vs

Side-by-side financial comparison of CABOT CORP (CBT) and HYSTER-YALE, INC. (HY). Click either name above to swap in a different company.

HYSTER-YALE, INC. is the larger business by last-quarter revenue ($923.2M vs $849.0M, roughly 1.1× CABOT CORP). CABOT CORP runs the higher net margin — 8.6% vs -5.7%, a 14.3% gap on every dollar of revenue. On growth, CABOT CORP posted the faster year-over-year revenue change (-11.1% vs -13.5%). CABOT CORP produced more free cash flow last quarter ($57.0M vs $32.9M). Over the past eight quarters, HYSTER-YALE, INC.'s revenue compounded faster (-6.5% CAGR vs -8.7%).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Hyster-Yale Materials Handling, Inc., through its wholly owned operating subsidiary, Hyster-Yale Group, Inc., designs, engineers, manufactures, sells and services a comprehensive line of lift trucks and aftermarket parts marketed globally primarily under the Hyster and Yale brand names. It was spun off from NACCO Industries in 2012, but had been running as a standalone company within NACCO since 2002.

CBT vs HY — Head-to-Head

Bigger by revenue
HY
HY
1.1× larger
HY
$923.2M
$849.0M
CBT
Growing faster (revenue YoY)
CBT
CBT
+2.4% gap
CBT
-11.1%
-13.5%
HY
Higher net margin
CBT
CBT
14.3% more per $
CBT
8.6%
-5.7%
HY
More free cash flow
CBT
CBT
$24.1M more FCF
CBT
$57.0M
$32.9M
HY
Faster 2-yr revenue CAGR
HY
HY
Annualised
HY
-6.5%
-8.7%
CBT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBT
CBT
HY
HY
Revenue
$849.0M
$923.2M
Net Profit
$73.0M
$-52.5M
Gross Margin
24.9%
14.2%
Operating Margin
15.2%
-4.0%
Net Margin
8.6%
-5.7%
Revenue YoY
-11.1%
-13.5%
Net Profit YoY
-21.5%
-609.7%
EPS (diluted)
$1.37
$-2.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
HY
HY
Q4 25
$849.0M
$923.2M
Q3 25
$899.0M
$979.1M
Q2 25
$923.0M
$956.6M
Q1 25
$936.0M
$910.4M
Q4 24
$955.0M
$1.1B
Q3 24
$1.0B
$1.0B
Q2 24
$1.0B
$1.2B
Q1 24
$1.0B
$1.1B
Net Profit
CBT
CBT
HY
HY
Q4 25
$73.0M
$-52.5M
Q3 25
$43.0M
$-2.3M
Q2 25
$101.0M
$-13.9M
Q1 25
$94.0M
$8.6M
Q4 24
$93.0M
$10.3M
Q3 24
$137.0M
$17.2M
Q2 24
$109.0M
$63.3M
Q1 24
$84.0M
$51.5M
Gross Margin
CBT
CBT
HY
HY
Q4 25
24.9%
14.2%
Q3 25
24.5%
15.9%
Q2 25
26.4%
17.6%
Q1 25
25.7%
19.5%
Q4 24
24.6%
19.4%
Q3 24
24.0%
19.0%
Q2 24
25.2%
22.2%
Q1 24
24.1%
22.3%
Operating Margin
CBT
CBT
HY
HY
Q4 25
15.2%
-4.0%
Q3 25
15.2%
0.2%
Q2 25
18.1%
-0.9%
Q1 25
17.3%
2.3%
Q4 24
16.2%
3.0%
Q3 24
15.0%
3.3%
Q2 24
16.9%
8.2%
Q1 24
15.3%
7.9%
Net Margin
CBT
CBT
HY
HY
Q4 25
8.6%
-5.7%
Q3 25
4.8%
-0.2%
Q2 25
10.9%
-1.5%
Q1 25
10.0%
0.9%
Q4 24
9.7%
1.0%
Q3 24
13.7%
1.7%
Q2 24
10.7%
5.4%
Q1 24
8.2%
4.9%
EPS (diluted)
CBT
CBT
HY
HY
Q4 25
$1.37
$-2.97
Q3 25
$0.80
$-0.13
Q2 25
$1.86
$-0.79
Q1 25
$1.69
$0.48
Q4 24
$1.67
$0.57
Q3 24
$2.41
$0.97
Q2 24
$1.94
$3.58
Q1 24
$1.49
$2.93

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
HY
HY
Cash + ST InvestmentsLiquidity on hand
$230.0M
Total DebtLower is stronger
$251.9M
Stockholders' EquityBook value
$1.6B
$472.0M
Total Assets
$3.8B
$2.0B
Debt / EquityLower = less leverage
0.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
HY
HY
Q4 25
$230.0M
Q3 25
$258.0M
Q2 25
$239.0M
Q1 25
$213.0M
Q4 24
$183.0M
Q3 24
$223.0M
Q2 24
$197.0M
Q1 24
$206.0M
Total Debt
CBT
CBT
HY
HY
Q4 25
$251.9M
Q3 25
$1.1B
$252.2M
Q2 25
$245.2M
Q1 25
$242.6M
Q4 24
$241.9M
Q3 24
$1.1B
$247.4M
Q2 24
$248.5M
Q1 24
$239.7M
Stockholders' Equity
CBT
CBT
HY
HY
Q4 25
$1.6B
$472.0M
Q3 25
$1.6B
$536.0M
Q2 25
$1.5B
$544.7M
Q1 25
$1.4B
$510.0M
Q4 24
$1.4B
$475.1M
Q3 24
$1.4B
$529.9M
Q2 24
$1.3B
$465.7M
Q1 24
$1.4B
$412.1M
Total Assets
CBT
CBT
HY
HY
Q4 25
$3.8B
$2.0B
Q3 25
$3.8B
$2.1B
Q2 25
$3.8B
$2.1B
Q1 25
$3.8B
$2.1B
Q4 24
$3.6B
$2.0B
Q3 24
$3.7B
$2.2B
Q2 24
$3.6B
$2.1B
Q1 24
$3.6B
$2.1B
Debt / Equity
CBT
CBT
HY
HY
Q4 25
0.53×
Q3 25
0.70×
0.47×
Q2 25
0.45×
Q1 25
0.48×
Q4 24
0.51×
Q3 24
0.75×
0.47×
Q2 24
0.53×
Q1 24
0.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
HY
HY
Operating Cash FlowLast quarter
$126.0M
$56.5M
Free Cash FlowOCF − Capex
$57.0M
$32.9M
FCF MarginFCF / Revenue
6.7%
3.6%
Capex IntensityCapex / Revenue
8.1%
2.6%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$401.0M
$23.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
HY
HY
Q4 25
$126.0M
$56.5M
Q3 25
$219.0M
$37.1M
Q2 25
$249.0M
$28.9M
Q1 25
$73.0M
$-36.4M
Q4 24
$124.0M
$80.7M
Q3 24
$204.0M
$70.1M
Q2 24
$207.0M
$-2.5M
Q1 24
$176.0M
$22.4M
Free Cash Flow
CBT
CBT
HY
HY
Q4 25
$57.0M
$32.9M
Q3 25
$155.0M
$22.6M
Q2 25
$188.0M
$15.1M
Q1 25
$1.0M
$-47.0M
Q4 24
$47.0M
$62.8M
Q3 24
$112.0M
$59.9M
Q2 24
$155.0M
$-14.7M
Q1 24
$133.0M
$14.9M
FCF Margin
CBT
CBT
HY
HY
Q4 25
6.7%
3.6%
Q3 25
17.2%
2.3%
Q2 25
20.4%
1.6%
Q1 25
0.1%
-5.2%
Q4 24
4.9%
5.9%
Q3 24
11.2%
5.9%
Q2 24
15.3%
-1.3%
Q1 24
13.1%
1.4%
Capex Intensity
CBT
CBT
HY
HY
Q4 25
8.1%
2.6%
Q3 25
7.1%
1.5%
Q2 25
6.6%
1.4%
Q1 25
7.7%
1.2%
Q4 24
8.1%
1.7%
Q3 24
9.2%
1.0%
Q2 24
5.1%
1.0%
Q1 24
4.2%
0.7%
Cash Conversion
CBT
CBT
HY
HY
Q4 25
1.73×
Q3 25
5.09×
Q2 25
2.47×
Q1 25
0.78×
-4.23×
Q4 24
1.33×
7.83×
Q3 24
1.49×
4.08×
Q2 24
1.90×
-0.04×
Q1 24
2.10×
0.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

HY
HY

Sales Channel Through Intermediary$281.7M31%
Aftermarketsales$179.1M19%
Sales Channel Directly To Consumer$173.6M19%
EMEAHY$153.3M17%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$89.0M10%
Otherrevenue$42.4M5%

Related Comparisons